fbpx

Blog

PSA continues to show leadership on ensuring the safe and quality use of medicines

Monday 26 August 2019

 

As part of its ongoing commitment to the safe and quality use of medicines, the Pharmaceutical Society of Australia (PSA) recently convened meetings to discuss improvements in the labelling and counselling for antibiotics and opioids by pharmacists.

 

Attended by medical, government, pharmacy and consumer stakeholders, and chaired by Emeritus Professor Lloyd Sansom AO, the meetings focused on reviewing cautionary advisory labels (CALs) and their associated advice. CALs are a convenient and effective way for pharmacists to reinforce verbal communication with patients about the safe and effective use and storage of medicines.

 

PSA National President Dr Chris Freeman said the meetings were important in continuing to address the issues of antimicrobial resistance and opioid-related harm.

 

“Actions three and five of our Pharmacists in 2023 report, look at embedding pharmacists within healthcare teams to improve medicine-related decision making; and advancing pharmacist stewardship of medicine management to improve outcomes at transition of care,” he said.

 

“Through these measures pharmacists will be empowered to not only play a greater role in addressing antimicrobial resistance and opioid-related harm, but improving the overall safe and quality use of medicines in Australia’s healthcare system.

 

“This builds on PSA’s position on antibiotics as shown through our Choosing Wisely recommendation 3 – do not dispense a repeat prescription for an antibiotic without first clarifying clinical appropriateness.”

 

The Australian Pharmaceutical Formulary and Handbook (APF), published by PSA, includes wording for a range of standard CALs and provides guidance on their use for specific medicines. By providing CALs and other written information alongside their professional advice, pharmacists can ensure patients are fully aware of why they are taking a medicine, understand how to take their medicine safely, and have the opportunity to ask questions.

 

 

Media contact:   Carly Lusk, Public Affairs Officer – 0487 922 176

A tailored approach needed for rural pharmacy

Wednesday 21 August 2019

 

In response to the National Rural Health Commissioner’s Discussion Paper for Consultation: Rural Allied Health Quality, Access and Distribution, the Pharmaceutical Society of Australia (PSA) has called for a number of actions to address the unique needs of the rural pharmacy workforce.

 

PSA National President Dr Chris Freeman said that rural pharmacy needed to be considered as a distinct entity and its specific challenges and required support structures were not adequately addressed within the discussion paper. There is a unique opportunity to support innovative practice within rural Australia through community pharmacy, and flexible integrated services should be developed as a matter of priority.

 

“Rural pharmacists are faced with unique challenges and PSA is calling for a tailored solution to ensure they are able to practise to their full scope and best manage the healthcare needs of their communities,” he said.

 

As a matter of urgency, PSA has asked the Commissioner to develop a discussion paper on ‘Rural Pharmacy Quality, Access and Distribution’. The current discussion paper is not fit for purpose for rural pharmacy and for the pharmacists that work in rural Australia. Unless we prioritise the supports that are available to our rural practitioners, we will potentially lose our rural community pharmacies, our rural pharmacists and a level of service delivery that will only further increase the gap between the outcomes for rural patients and their urban counterparts.

 

As the most accessible healthcare provider, pharmacists are well-placed to perform a much greater role in Australia’s rural and remote communities, however they urgently need more support. PSA members in rural and remote Australia report that workforce maldistribution, higher levels of socioeconomic disadvantage and lack of rural medical practitioners put further pressure on an already strained community pharmacy workforce.

 

“PSA holds great fears about the sustainability of, and therefore access to, pharmacy services within rural communities and now is the time for action,” Dr Freeman said.

 

“Community pharmacies in rural and remote Australia are unique because they represent a private investment in health infrastructure that is generally not present through other allied health practitioners.”

 

PSA made a number of other recommendations to the Commissioner, including:

  • identifying rural pharmacy workforce distribution, needs and opportunities
  • reviewing rural health workforce support programs and initiatives to ensure equity of access to appropriate support for pharmacists, similar to the medical and nursing professions
  • fully utilising the infrastructure of community pharmacy through the delivery of a rural pharmacy strategic framework
  • investing in trials to implement innovative rural-based models of care by allowing greater flexibility in funding and delivery of pharmacist care tailored to rural and remote communities’ needs.

 

PSA is urgently seeking to address these issues with the National Rural Health Commissioner and the Minister responsible for rural health to progress these actions for the benefit of rural and remote pharmacists and the communities they serve.

 

PSA’s full submission is available on our website.

 

Media contact:      Carly Lusk, Public Affairs Officer – 0487 922 176

Pharmacists – experts in the language of medicines

Monday 19 August 2019

 

Be Medicinewise Week 2019 is about getting to know the language of medicines – and pharmacists are best placed to assist patients gain this knowledge.

 

As part of NPS Medicinewise’s Be Medicinewise Week, the Pharmaceutical Society of Australia (PSA) is encouraging people to talk to their pharmacist to increase their understanding of their medicines.

 

PSA National President Dr Chris Freeman said pharmacists’ first priority was the health and wellbeing of patients and they were committed to supporting patients through every step of their care.

 

“As medicine experts, pharmacists speak the language of medicines and can help patients not only increase their health literacy, but empower them to be active participants in their health care,” he said.

 

“This, in turn, will help reduce medicine-related problems and improve patient health outcomes.”

 

PSA’s Medicine Safety: Take Care report revealed that medicine-related problems cause 250,000 hospital admissions and 400,000 emergency department presentations in Australia each year, costing the healthcare system $1.4 billion annually. At least half of this harm is avoidable, and pharmacists are the key to improving the safe and quality use of medicines.

 

“PSA encourages people to speak to their pharmacist whenever there is a change in their medicines or health circumstances, or anytime they have concerns,” Dr Freeman said.

 

“Pharmacists are uniquely placed within the healthcare system and the frequency with which they interact with patients means they are best equipped to identify a medicine-related issue and resolve it immediately.”

 

PSA is proud to support Be Medicinewise Week and NPS Medicinewise’s ongoing work to increase the safe and quality use of medicines.

 

PSA echoes NPS Medicinewise’s call for patients to know all the medicines they are taking and why they are taking them, understand the instructions on how to take their medicines, and ask pharmacists any questions they have about their medicines.

 

Be MedicinewiseWeek 2019 runs from 19-25 August. To learn more visit: nps.org.au/bemedicinewise.

 

 

Media contact:   Carly Lusk, Public Affairs Officer – 0487 922 176

Absence from Work Guidelines & certificate templates

Access PSA’s Absence from Work Guidelines and Resources here

WA expands scope of pharmacist-administered vaccinations

Thursday 1 August 2019

 

The Pharmaceutical Society of Australia (PSA) welcomes today’s announcement from WA Health Minister the Hon Roger Cook MLA to expand the scope of pharmacist-administered vaccinations.

 

PSA WA Branch President Dr Fei Sim commended the government’s decision to allow pharmacists to protect more West Australians 16 years and over from dTpa (diphtheria, tetanus and pertussis), MMR (measles, mumps and rubella) and meningococcal (ACWY).

 

“Allowing trained pharmacists to administer these vaccines will significantly increase the immunisation rates within the community,” she said.

 

“While Australia has a strong childhood vaccination program, there are many areas in Australia with vaccination rates still below the level of coverage required for herd immunity, including for dTpa and MMR. Pharmacists can play a key role in addressing this issue.”

 

Research has shown internationally and locally that pharmacists are considered highly accessible and enabling them to vaccinate against more preventable diseases will help reduce the burden on our already over-burdened healthcare system.

 

Independent research commissioned by PSA has revealed almost two-in-three Australians believe pharmacists should be able to administer a broader range of vaccinations. PSA commends the WA Government for enabling the profession to do just this.

 

The recent increase in measles cases in Australia, highlights the need to increase the accessibility of this vaccine and the need for a national approach to pharmacist-administered vaccinations.

 

“PSA continues to advocate for a national approach to pharmacist-administered vaccinations to reduce confusion, ensure better access for patients to quality vaccination services and utilise the pharmacy workforce appropriately,” Dr Sim said.

 

“The introduction of pharmacist-administered MMR vaccinations in Western Australia is a great step forward, leaving Tasmania and the ACT as the only two jurisdictions where pharmacists cannot vaccinate against these diseases.”

 

The administration of vaccines by pharmacists complements the excellent work done by GPs, nurses, Indigenous Health Workers and other immunisers.

 

PSA commends the WA Government for making use of pharmacists’ expertise and training to better protect the community against vaccine-preventable diseases.

 

Photo: PSA WA Branch President Dr Fei Sim

 

Media contact:   Carly Lusk, Public Affairs Officer – 0487 922 176

NSW Health Minister officially opens PSA office

29 July 2019

 

NSW Minister for Health and Medical Research the Hon Brad Hazzard MP today officially opened the Pharmaceutical Society of Australia’s (PSA) NSW office in North Sydney.

 

PSA NSW Branch President Professor Peter Carroll thanked Minister Hazzard for his attendance and acknowledged his efforts in providing better access to health and medicines in NSW – particularly in relation to the recent expansion of pharmacist-administered vaccination in NSW. This now includes influenza, measles mumps rubella and diphtheria tetanus and pertussis in patients 16 years and over.

 

“This has been a huge success and benefit to the people of NSW and we thank the Minister for making this a reality,” Professor Carroll said.

 

“We look forward to continuing this work with the Minister, particularly around the medicine safety priority, so that pharmacists in NSW can ensure patients use medicines safely and effectively.

 

“We also look forward to delivering better mental health care, because we know pharmacists are skilled and accessible health care professionals who will make a huge difference for patients.”

 

Professor Carroll also thanked NSW Health Chief Pharmacist Judith Mackson for her attendance at today’s event and her commitment to improving healthcare in the state.

 

The original PSA NSW Office was located in Science House in the CBD, before moving to St Leonards in 1976. The new office is located in Ridge Street, North Sydney and provides not only a workspace for PSA NSW staff but a wonderful location for PSA members to connect, develop professionally and celebrate the history of the pharmacy profession.

 

Photo: (L-R) NSW Minister for Health and Medical Research the Hon Brad Hazzard MP and PSA NSW Branch President Professor Peter Carroll, Pharmacy House NSW

 

Media contact:   Carly Lusk, Public Affairs Officer – 0487 922 176

Alice Hashiguchi wins 2019 PSA Mylan Pharmacy Student of the Year award

27 July 2019

 

Alice Hashiguchi from the University of Western Australia has won the 2019 PSA Mylan Pharmacy Student of the Year (PSOTY) Award, announced at the PSA19 Gala Dinner in Sydney tonight.

 

PSA National President Dr Chris Freeman congratulated Ms Hashiguchi on her exceptional achievement.

 

“The PSOTY Award gives outstanding pharmacy students the chance to showcase their counselling skills to their peers and the wider profession,” Dr Freeman said.

 

“We saw many rising stars of pharmacy apply their clinical knowledge and communication skills in this year’s competition.”

 

Kiralee Gross from James Cook University took home the People’s Choice award.

 

The judges were impressed by the strong field of finalists:

 

  • Alice Hashiguchi, University of Western Australia
  • Kiralee Gross, James Cook University
  • Alyssa Murray, University of Queensland
  • Patrick Bevan, University of Tasmania
  • Sadaf Keshtiar, Monash University
  • Samuel Watts, Monash University.

 

This year’s competition was once again sponsored by Mylan. The winner receives the National Travel Prize for pharmacy-specific education of an expenses-paid trip to a pharmacy conference.

 

Mylan Country Manager Sylvain Vigneault spoke of the organisation’s ongoing support of pharmacy students.

 

“Mylan has been a proud supporter the Pharmacy Student of the Year award since its inception.

 

“We recognise the important contribution that pharmacists make in facilitating better patient outcomes within their community. We feel strongly about encouraging pharmacy students to learn, grow and explore the role they will play, delivering better health in Australia,” he said.

 

“PSA thanks Mylan for their ongoing support of this award,” Dr Freeman said.

 

Photo caption: (L-R) 2019 PSA Mylan Pharmacy Student of the Year Ms Alice Hashiguchi and Mylan Marketing Manager – Pharmacy Ms Jordana Sunderland

 

Media contact: Carly Lusk, Public Affairs Officer, 0487 922 176

Ayomide Ogundipe wins 2019 Intern Pharmacist of the Year

Saturday 27 July 2019

 

Talented intern pharmacist Ayomide (Mide) Ogundipe is the winner of the 2019 PSA MIMS Intern Pharmacist of the Year Award.

 

Presented at PSA’s flagship conference PSA19 today, the award recognises intern pharmacists who demonstrate outstanding performance in their development as professional pharmacists, acting as role models amongst Early Career Pharmacists (ECP).

 

Ms Ogundipe completed her internship at Pharmacy 777 in Perth in 2018.

 

During her intern year she was actively involved in PSA’s ECP Working Group in WA, was Executive Director of Public Relations at the National Australian Pharmacy Students’ Association (NAPSA), and played a significant role in driving the International Pharmaceutical Students’ Federation (IPSF) Asia Pacific Regional Office initiatives.

 

Ms Ogundipe also successfully introduced a number of innovative programs and services to her practice, including Your Health Expo.

 

In accepting her award, Ms Ogundipe said her greatest learning experience as an intern was deciding her areas of interest and developing her professional practice in a manner that allows her to have a solutions-based outlook. She also provided advice to new pharmacy interns.

 

“Take ownership of your role and allow yourself to stay teachable – you are a few steps away from your general registration, use the year to consolidate everything you’ve learnt throughout your studies, build your professional experience and find areas that interest you. There is something to learn from everyone,” she said.

 

MIMS Australia is the leading sponsor of the award and contributed the major prize of $5,000 for the winner to put towards attending any pharmacy or educational conference approved by PSA.

 

Robert Best, CEO of MIMS Australia and New Zealand said, “For over 55 years, MIMS has been and continues to be, committed to supporting young healthcare professionals from all parts of the healthcare ecosystem.

 

“It is with immense pleasure that we support community and hospital pharmacists and the interns within them by providing world class medications information that support excellence in patient care and medication management.

 

“Being able to reward excellence in young innovative people and recognise their outstanding contributions is extremely exciting for the entire team at MIMS. These interns are the future of pharmacy!”

 

PSA National President Dr Chris Freeman congratulated Ms Ogundipe on her achievements and dedication to the profession.

 

“Ms Ogundipe completed her internship to an exceptionally high standard, showing great initiative and openness to collaboration,” Dr Freeman said.

 

Photo: (L-R) CEO of MIMS Australia and New Zealand Mr Robert Best; 2019 PSA MIMS Intern Pharmacist of the Year Ms Ayomide (Mide) Ogundipe; and PSA National President Dr Chris Freeman

 

Media contact: Carly Lusk, Public Affairs Officer, 0487 922 176

New PSA fellows recognised for outstanding service to the profession

Saturday 27 July 2019

 

The Pharmaceutical Society of Australia (PSA) last night announced seven new Fellows in recognition of their outstanding contribution to PSA and the pharmacy profession.

 

The 2019 PSA Fellows are:

 

  • Mr Tim Perry, NSW

Mr Perry has owned and managed community pharmacies in Sydney for 25 years. In recent times, he has worked as a non-dispensing Clinical Pharmacist in various medical practices. He also established his own Medicines Review Company, playing a key role in medicine safety through the provision of HMRs and RMMRs in collaboration with community pharmacies, GPs and other healthcare teams.

 

  • A/Prof Rebekah Moles, NSW

A/Prof Moles is a pharmacist with experience in community and hospital pharmacy as well as research into the Quality Use of Medicines both in pediatric dosing and in transitions of care – post hospital discharge. She has dedicated much of her time to both the education and professional development of pharmacists across Australia. She is also a volunteer on PSA’s NSW Branch Committee where she supports PSA’s advocacy messages through meetings with state and federal politicians.

 

  • Mr Phil Dibben, NSW

Mr Dibben has been a community pharmacy owner for over 40 years in the Newcastle area. In the 1990s, he was influential in bringing Breath-a-Tech, a revolutionary asthma treatment device, to the market. He was also instrumental in the establishment of the Master of Pharmacy Program at the University of Newcastle where he is a member of the pharmacy advisory group.

 

  • Mrs Karen Carter, NSW

Mrs Carter is a community pharmacy owner in Gunnedah and Narrabri. She has worked in both hospital and community pharmacy across the span of her pharmacy career and is also an accredited pharmacist – providing HMRs and RMMRs. Recognising the severe impacts of the drought in her region, Mrs Carter was proactive in liaising with PSA to establish a course to ensure pharmacists were equipped to best support the mental health challenges faced by the community.

 

  • Dr Claire O’Reilly, NSW

Dr Claire O’Reilly is a Senior Lecturer at the University of Sydney Pharmacy School.

She was previously National Vice President of PSA (2011-2014) and was the first pharmacist to be appointed to the Medical Services Advisory Committee, which provides advice to the Federal Government on the strength of evidence for the safety, effectiveness and cost-effectiveness of medical technologies.

 

  • Mr Bill Suen, VIC

Mr Suen contributed to a number of pharmacy practice changes during his tenure as PSA Victoria State Manager. He worked with the Victorian Branch Committee to establish the Victorian Family Tree mentoring program to support young pharmacists and PSA members develop their careers. This has now evolved into a national mentoring program. He also advocated for developments in pharmacy practice including: pharmacist-administered vaccinations; real-time prescription monitoring; and pharmacotherapy training and enhanced roles for pharmacists.

 

  • Ms Michelle Lynch, VIC

Ms Lynch is the National Hospital Pharmacy Manager at Ramsay Health Care and current PSA National Vice President. She has previously served as PSA Victoria Branch Committee Vice President and President. One of her most significant contributions to the profession was in the Parliamentary Inquiry into the roles and opportunities for community pharmacy in primary and preventative care in Victoria in 2014. Speaking at the inquiry, she advocated for expanding the role of pharmacists to improve health outcomes and reduce medicine-related harm.

 

PSA National President Dr Chris Freeman congratulated the new Fellows and acknowledged the significant impact they have had throughout their careers.

 

“Each of the people recognised this evening have made, and continue to make, outstanding contributions to the pharmacy profession,” he said.

 

“On behalf of PSA, I thank them for their ongoing service and dedication to improving pharmacy practice and patient care.”

 

Photo caption: (L-R) Dr Chris Freeman; Dr Claire O’Reilly; A/Prof Rebekah Moles; Ms Michelle Lynch; Mr Tim Perry, Mr Phil Dibben; Mrs Karen Carter

 

 

Media contact: Carly Lusk, Public Affairs Officer, 0487 922 176

Roles and remuneration: unlocking opportunities for pharmacists to support improved patient care

Saturday 27 July 2019

 

The Pharmaceutical Society of Australia today launched its new report Pharmacists in 2023: Roles and Remuneration which describes the current and future roles of pharmacists and fair remuneration for their professional contribution.

 

PSA National President Dr Chris Freeman said that remuneration for Australian pharmacists did not, in the main, reflect their skills, training, expertise or responsibility in the healthcare system, and changing this is the most important issue for PSA members.

 

“As the complexity of pharmacy practice increases, pharmacists need properly remunerated and supported career pathways,” he said.

 

“Our new roles and remuneration report provides the pathway to achieve increased remuneration by 2023 – remuneration that reflects the value that pharmacists deliver in patient care.”

 

In constructing the salary ranges, PSA looked at other health professions with similar training and expertise, here in Australia, and internationally.

 

It is PSA’s view that the most appropriate mechanism to support increased remuneration for pharmacists is to link remuneration with activity as well as the skills, expertise, and training of the pharmacist.

 

“The Advanced Practice Framework is the most logical application of this and, while this may take some time to implement, it is clear we need to forge a path that delivers better value for pharmacists – we believe this is the way,” Dr Freeman said.

 

Dr Freeman said that PSA believed that pharmacists need to be valued appropriately in order to retain the best and brightest in the profession.

 

“We will therefore continue to advocate for pharmacists – for recognition of their training, expertise and role as custodians of medicine safety – and the reflection of these in remuneration packages,” Dr Freeman said.

 

“We call on other stakeholder groups and the Australian Government to work together to achieve the necessary changes.”

 

Media contact:
Carly Lusk
Public Affairs Officer
0487 922 176